# A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

> **NCT05259917** · PHASE3 · COMPLETED · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 136 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** Placebo
- **DRUG:** KVD900 600 mg
- **DRUG:** KVD900 300 mg

## Key facts

- **NCT ID:** NCT05259917
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-22
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05259917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05259917, "A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05259917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*